These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 18818399)

  • 21. Demonstrating the value of orthopaedic surgery through multicenter trials: AOA critical issues.
    Hilibrand AS; Spindler K; O'Keefe RJ
    J Bone Joint Surg Am; 2015 Apr; 97(7):e35. PubMed ID: 25834087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are clinical trials a cost-effective investment?
    Detsky AS
    JAMA; 1989 Oct; 262(13):1795-800. PubMed ID: 2506366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accounting for future populations in health research.
    Pierson L
    Bioethics; 2024 Jun; 38(5):401-409. PubMed ID: 38602177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NeuroAIDS research in resource-limited countries. Emerging priorities of the U.S. National Institute of Mental Health and the National Institute of Neurological Disorders and Stroke.
    Joseph J; Kopnisky KL; Nunn M
    J Neurovirol; 2005; 11 Suppl 1():1-3. PubMed ID: 15960233
    [No Abstract]   [Full Text] [Related]  

  • 25. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context.
    Toth PP; Danese M; Villa G; Qian Y; Beaubrun A; Lira A; Jansen JP
    J Med Econ; 2017 Jun; 20(6):555-564. PubMed ID: 28097904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health policy in stroke: translating what we know into what we do.
    Matchar DB
    Stroke; 2003 Feb; 34(2):370-1. PubMed ID: 12574540
    [No Abstract]   [Full Text] [Related]  

  • 27. The NIMH perspective: next steps in schizophrenia research.
    Hyman SE
    Biol Psychiatry; 2000 Jan; 47(1):1-7. PubMed ID: 10650443
    [No Abstract]   [Full Text] [Related]  

  • 28. Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial.
    Kongnakorn T; Ward A; Roberts CS; O'Brien JA; Proskorovsky I; Caro JJ
    Value Health; 2009 Sep; 12(6):880-7. PubMed ID: 19490555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conducting stroke research with an exception from the requirement for informed consent.
    Bateman BT; Meyers PM; Schumacher HC; Mangla S; Pile-Spellman J
    Stroke; 2003 May; 34(5):1317-23. PubMed ID: 12663878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of the National Institutes of Health on radiology research.
    Itagaki MW
    Radiology; 2008 Apr; 247(1):213-9. PubMed ID: 18372469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. William M. Feinberg Lecture: stroke therapy in the year 2025: burden, breakthroughs, and barriers to progress.
    Broderick JP
    Stroke; 2004 Jan; 35(1):205-11. PubMed ID: 14671248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Executive summary of the National Institute of Neurological Disorders and Stroke conference on Emergency Neurologic Clinical Trials Network.
    Barsan WG; Pancioli AM; Conwit RA
    Ann Emerg Med; 2004 Oct; 44(4):407-12. PubMed ID: 15459625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy.
    Tunis SR; Stryer DB; Clancy CM
    JAMA; 2003 Sep; 290(12):1624-32. PubMed ID: 14506122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What strategy should France implement for H2020?
    Dhainaut JF; Diebolt V; Pouletty-Lefèbvre B; ; Baker A; Bassompierre F; Borel T; Braunstein D; Demotes J; François B; Huet S; Micallef J; Misse C; Molon A; Rascol O; Ravoire S; Schwartz B; Donne N; Donne N; Fusaï G; Pouletty P; Vicaut E
    Therapie; 2015; 70(1):95-109. PubMed ID: 25747841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Time to Publication of Clinical Trials Funded by the National Institute of Neurological Disorders and Stroke.
    Brown J; Wakim PG; Faraco C; Saugar-Lanchas C; Lungu C; Mendoza-Puccini C; Rosenberg E; Wright C
    Ann Neurol; 2021 Dec; 90(6):861-864. PubMed ID: 34713927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identifying and pursuing research priorities at the National Center for Complementary and Alternative Medicine.
    Nahin RL
    FASEB J; 2005 Aug; 19(10):1209-15. PubMed ID: 16051686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cost-effectiveness of telestroke in the Pacific Northwest region of the USA.
    Nelson RE; Okon N; Lesko AC; Majersik JJ; Bhatt A; Baraban E
    J Telemed Telecare; 2016 Oct; 22(7):413-21. PubMed ID: 26541170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrating value of research into NCI Clinical Trials Cooperative Group research review and prioritization: A pilot study.
    Carlson JJ; Kim DD; Guzauskas GF; Bennette CS; Veenstra DL; Basu A; Hendrix N; Hershman DL; Baker L; Ramsey SD
    Cancer Med; 2018 Sep; 7(9):4251-4260. PubMed ID: 30030904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [How much does the society want to pay?].
    Norheim OF
    Tidsskr Nor Laegeforen; 2003 Feb; 123(3):303. PubMed ID: 12640893
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.